Incretin-based therapy of metabolic disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Incretin-based therapy of metabolic disease. / Holst, Jens Juul.

In: Danish Medical Journal, Vol. 70, No. 1, A10220597, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Holst, JJ 2023, 'Incretin-based therapy of metabolic disease', Danish Medical Journal, vol. 70, no. 1, A10220597. <https://ugeskriftet.dk/dmj/incretin-based-therapy-metabolic-disease>

APA

Holst, J. J. (2023). Incretin-based therapy of metabolic disease. Danish Medical Journal, 70(1), [A10220597]. https://ugeskriftet.dk/dmj/incretin-based-therapy-metabolic-disease

Vancouver

Holst JJ. Incretin-based therapy of metabolic disease. Danish Medical Journal. 2023;70(1). A10220597.

Author

Holst, Jens Juul. / Incretin-based therapy of metabolic disease. In: Danish Medical Journal. 2023 ; Vol. 70, No. 1.

Bibtex

@article{2d6a221b83954064ad1a8d989e2ab865,
title = "Incretin-based therapy of metabolic disease",
abstract = "Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.",
author = "Holst, {Jens Juul}",
note = "Publisher Copyright: {\textcopyright} 2023, Almindelige Danske Laegeforening. All rights reserved.",
year = "2023",
language = "English",
volume = "70",
journal = "Danish Medical Journal",
issn = "2245-1919",
publisher = "Almindelige Danske Laegeforening",
number = "1",

}

RIS

TY - JOUR

T1 - Incretin-based therapy of metabolic disease

AU - Holst, Jens Juul

N1 - Publisher Copyright: © 2023, Almindelige Danske Laegeforening. All rights reserved.

PY - 2023

Y1 - 2023

N2 - Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.

AB - Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.

UR - http://www.scopus.com/inward/record.url?scp=85148425752&partnerID=8YFLogxK

M3 - Journal article

AN - SCOPUS:85148425752

VL - 70

JO - Danish Medical Journal

JF - Danish Medical Journal

SN - 2245-1919

IS - 1

M1 - A10220597

ER -

ID: 340118796